Primary myelofibrosis Advocacy Hub | UniteRare

At a Glance

Live from database

💊

Regulatory Watchboard

10 events

Nov 2026Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis

United Lincolnshire Hospitals NHS Trust — PHASE2

TrialNOT YET RECRUITING

Aug 2026Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts

SWOG Cancer Research Network — PHASE4

TrialNOT YET RECRUITING

Apr 2026To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — PHASE1

TrialNOT YET RECRUITING

Mar 2026Therapeutic RSK1 Targeting in Myelofibrosis

Washington University School of Medicine — PHASE1

TrialNOT YET RECRUITING

Mar 2026Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis

Institute of Hematology & Blood Diseases Hospital, China — PHASE2

TrialNOT YET RECRUITING

Mar 2026Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia

Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas — PHASE2

TrialNOT YET RECRUITING

Feb 2026Momelotinib During and After HCT in Myelofibrosis

Massachusetts General Hospital — PHASE1

TrialRECRUITING

Feb 2026A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

Chengdu Zenitar Biomedical Technology Co., Ltd — PHASE3

TrialRECRUITING

Jan 2026Momelotinib Effectiveness in Myelofibrosis

Gruppo Italiano Malattie EMatologiche dell'Adulto

TrialNOT YET RECRUITING

Jan 2026Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

M.D. Anderson Cancer Center — PHASE1, PHASE2

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Primary myelofibrosis.
Check the disease page for updates →

Approved Treatments

3 FDA-approved

Inrebic

(FEDRATINIB HYDROCHLORIDE)Orphan drugstandard

Celgene Corporation

FDA label ↗

Ojjaara

(MOMELOTINIB)Orphan drugstandard

GlaxoSmithKline LLC

FDA label ↗

Vonjo

(PACRITINIB)Orphan drugaccelerated

Sobi, Inc.

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

46 active trials

6Phase 3

1Phase 4

15Phase 2

6Phase 1

1N/A

7Unknown

10PHASE1, PHASE2

46Total recruiting

Search clinical trials for Primary myelofibrosis →

Recent News & Research

3 articles

BREAKINGFDA

FDA Approves VONJO

VONJO (PACRITINIB CITRATE) received FDA approval.

Read ↗

BREAKINGFDA

FDA Approves INREBIC

INREBIC (FEDRATINIB HYDROCHLORIDE) received FDA approval.

Read ↗

BREAKINGFDA

FDA Approves OJJAARA

OJJAARA (MOMELOTINIB DIHYDROCHLORIDE) received FDA approval.

Read ↗

Browse all Primary myelofibrosis news →

Specialist Network

Top 6 by expertise

Gabriela Hobbs, MD, MD

Massachusetts General Hospital

📍 BOSTON, MA

Score 384 trials1 pub

Rachel B. Salit, MD

Fred Hutch/University of Washington Cancer Consortium

📍 SEATTLE, WA

Score 374 trials

Jie Jin, PhD

Zhejiang University

Score 292 trials

Srdan Verstovsek, MD, M.D., PhD

M.D. Anderson Cancer Center

📍 HOUSTON, TX

Score 269 trials

Gautam Borthakur, M.D

M.D. Anderson Cancer Center

📍 HOUSTON, TX

Score 203 trials1 pub

Farhad Ravandi-Kashani, MD, M.D

M.D. Anderson Cancer Center

📍 HOUSTON, TX

Score 198 trials

View all Primary myelofibrosis specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰